Effects of risedronate on metabolic bone disease in patients with type 1 diabetes and osteoporosis
Rev. esp. enferm. metab. óseas (Ed. impr.)
; 17(4): 66-70, jul. 2008. tab
Article
en En
| IBECS
| ID: ibc-67075
Biblioteca responsable:
ES15.1
Ubicación: ES15.1 - BNCS
ABSTRACT
To assess the effect of a antiresorptive on bone mass and remodeling markers in patients with type 1 diabetes mellitus (DM-1) and osteoporosis (OP). Studyincluded 52 patients with DM-1 of 21-36 years duration and OP or osteopenia, aged 29-69 years. OP patients received 30 mg/week risedronate (n = 35)and calcium + vitamin D; osteopenic patients and risedronate refusers (n = 17) received only calcium + vitamin D. At 12 months, the risedronate group showedsignificant improvements in tartrate resistant acid phosphatase (p < 0.0001), osteocalcin (BGP) (p < 0.0001), bone alkaline phosphatase (BAP) (p < 0.0001),and hemoglobin A1c (HbA1c) (p < 0.0001); bone mineral density (BMD) was increased at 6 and 12 months versus baseline in lumbar spine (LS) (p < 0.0001) and femoral neck (FN) (p < 0.0001). At 12 months, the conventional group showed a significant improvement in HbA1c (p < 0.012) and reduction in BGP (p < 0.03) and BAP (p < 0.0001). The conventional treatment group showedno significant changes in BMD at LS and FN during the 12-month period. Risedronate treatment improves BMD in long-term DM-1 patients (AU)
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Enfermedades Óseas Metabólicas
/
Difosfonatos
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Rev. esp. enferm. metab. óseas (Ed. impr.)
Año:
2008
Tipo del documento:
Article